EPO and toxic diffuse goiter: Acute haematological toxicity was low. One patient with a previous history of grade IV thrombopenia with 90Y-DOTATOC therapy developed grade II thrombopenia with 213Bi-DOTATOC. During the long-term follow-up, three patients developed chronic anaemia. Erythropoietin levels in lower normal range were found in two patients. Graves’ disease (toxic diffuse goiter) was diagnosed one year after the last treatment cycle and must be considered therapy-associated because thyroid cells can also express somatostatin receptors.